Tanvex BioPharma (TPE:6541) LT-Debt-to-Total-Asset: 0.17 (As of Dec. 2025)

What is Tanvex BioPharma LT-Debt-to-Total-Asset?

Tanvex BioPharma TPE:6541 57 LT-Debt-to-Total-Asset is 0.17 as of Dec. 2025. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$255.45 (Possible Value Trap). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tanvex BioPharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.17.

Tanvex BioPharma's long-term debt to total assets ratio declined from Dec. 2024 (0.54) to Dec. 2025 (0.17). It may suggest that Tanvex BioPharma is progressively becoming less dependent on debt to grow their business.

Tanvex BioPharma (TPE:6541) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tanvex BioPharma LT-Debt-to-Total-Asset Related Terms

Tanvex BioPharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Tanvex BioPharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma LT-Debt-to-Total-Asset Chart

Tanvex BioPharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.35

0.50

0.57

0.54

0.17

Tanvex BioPharma Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.54	0.21	0.20	0.17	0.17

57GF Score

Tanvex BioPharma Inc TPE:6541

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Tanvex BioPharma LT-Debt-to-Total-Asset Calculation

Tanvex BioPharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1366.766	/	7961.134
	=	0.17

Tanvex BioPharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	1366.766	/	7961.134
	=	0.17

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.17 mean?

Tanvex BioPharma (TPE:6541) has a LT-Debt-to-Total-Asset of 0.17 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Tanvex BioPharma and its competitors.

Is Tanvex BioPharma's LT-Debt-to-Total-Asset too high?

Tanvex BioPharma's current LT-Debt-to-Total-Asset is 0.17. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Tanvex BioPharma's LT-Debt-to-Total-Asset compare to VRTX and REGN?

Tanvex BioPharma's LT-Debt-to-Total-Asset of 0.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current LT-Debt-to-Total-Asset is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Tanvex BioPharma stock overvalued right now?

Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$255.45, compared to a current price of NT$40.80 — trading 84% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.17. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current LT-Debt-to-Total-Asset is 0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?

Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued. The current stock price of NT$40.80 is trading 84% below its estimated GF Value™ of NT$255.45. GuruFocus considers Tanvex BioPharma to be Possible Value Trap.

Key valuation signals for TPE:6541:

LT-Debt-to-Total-Asset: 0.17
GF Value™: NT$255.45 vs. price of NT$40.80 (84% below fair value)
GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tanvex BioPharma Business Description

Industry Healthcare Biotechnology

Comparable Companies ROCO:6891 TPE:6550 ROCO:6945 ROCO:6748 ROCO:4162 ROCO:6617 TPE:4169 ROCO:6976 TPE:4142 TPE:6589 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106

Website https://www.tanvex.com

Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.

57GF Score

Get the complete analysis for TPE:6541

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.80

Price

NT$255.45

GF Value

View TPE:6541 Analysis

See LT-Debt-to-Total-Asset data for all stocks →